Denali Therapeutics (DNLI) Change in Acquisitions & Divestments (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Change in Acquisitions & Divestments data on file, last reported at $220.0 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $220.0 million, up 36.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $764.3 million (down 18.32% YoY), and the FY2025 annual result was $706.0 million, down 38.98% from the prior year.
• Change in Acquisitions & Divestments declined to $220.0 million in Q1 2026 per DNLI's latest filing, from $275.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $601.1 million in Q3 2023 and troughed at $107.1 million in Q3 2025.
• A 5-year average of $303.0 million and a median of $250.5 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments jumped 316.46% in 2023, then tumbled 67.06% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $364.0 million in 2022, then surged by 34.34% to $489.0 million in 2023, then declined by 28.22% to $351.0 million in 2024, then declined by 21.65% to $275.0 million in 2025, then decreased by 20.0% to $220.0 million in 2026.
• Business Quant data shows DNLI's Change in Acquisitions & Divestments at $220.0 million in Q1 2026, $275.0 million in Q4 2025, and $107.1 million in Q3 2025.